Physician profile
Jonelle A Mattis
NPI 1003331133
$628.90
in general payments reported to CMS, 2019-2025
11 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.30 · 2023: $22.55 · 2024: $19.16 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.60 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $142.69 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $113.44 | 2025 | Opdivo |
| Seagen INC. | $99.00 | 2025 | |
| Pfizer INC. | $80.12 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $47.80 | 2025 | |
| Merck Sharp & Dohme LLC | $26.32 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.19 | 2025 | |
| Gilead Sciences, INC. | $26.19 | 2025 | |
| Abbvie INC. | $24.37 | 2025 | |
| Genentech USA, INC. | $22.55 | 2023 | Columvi |
| Stemline Therapeutics INC. | $20.23 | 2025 | Elzonris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonelle Mattis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.